DUBLIN, August 17, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Systematic Lupus Erythematosus: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.
A shift in the systemic lupus erythematosus (SLE) market is forecast over the next 10 years, as new product approvals drive a movement from traditional off-label treatment to prescribing of approved therapies.
This report addresses the following questions:
- How has the approval of Benlysta impacted the treatment algorithm and clinical trial design?
- What will drive growth in the SLE market over the next 10 years, and which patient groups will be most impacted by new product launches?
- What factors have led to the late-phase clinical trial failures that continue to be seen in SLE?
- Which clinical attributes will a new drug need to demonstrate in order to compete in this market?
Key Topics Covered:
FORECAST: SYSTEMIC LUPUS ERYTHEMATOSUS
- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- anifrolumab
- Benlysta SLE (belimumab)
- blisibimod
- Primary Research Methodology
EPIDEMIOLOGY: SYSTEMIC LUPUS ERYTHEMATOSUS
- Executive Summary
- Sources and Methodology,
- Forecast,
- Epidemiologist Insight,
- Strengths and Limitations
MARKETED DRUGS: SYSTEMIC LUPUS ERYTHEMATOSUS
- Executive Summary,
- Product Overview,
- Primary Research Methodology,
- Product profile: Benlysta,
- Product profile: Off-label: CellCept,
- Product profile: Off-label: Rituxan
PIPELINE: SYSTEMIC LUPUS ERYTHEMATOSUS
- Executive Summary
- Clinical Pipeline Overview
- Comparator Therapy
- Clinical Trial Design
- The Future of Disease Treatment
- Recently Discontinued Drugs
- Primary Research Methodology
- Product profile (late stage): Lupuzor
- Product profile (late stage): anifrolumab
- Product profile (late stage): atacicept
- Product profile (late stage): blisibimod
For more information about this report visit http://www.researchandmarkets.com/research/xzm9jf/systematic_lupus
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
